Clinical Trial Update: Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa. [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of two dose levels of Arikayce in bronchiectasis with chronic Pseudomonas aeruginosa infection completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis

Drugs mentioned

• Arikayce (amikacin liposome inhalation suspension)

Snippet

Sponsor: Insmed Incorporated | Conditions: Bronchiectasis | Phase 2 | Status: COMPLETED | Results posted: 2019-07-10